Paolo Tarantino, 2025 Yvonne’s “Top Voice” Award Winner, Clinical Research Fellow at Dana-Farber Cancer Institute, Visiting Professor at McGill University, shared a post on LinkedIn:
“25 years ago, the entering of a HER2 mAb improved OS for HER2+ MBC from 20 to 25 months.
25 years later, the first-line implementation of a HER2 hashtag#ADC (T-DXd) led to a PFS of 40 months, with median survival expected to exceed 5 years.
Trastuzumab Deruxtecan plus Pertuzumab for HER2-Positive Metastatic Breast Cancer
Where will the next 25 years take us?
The goal: to eliminate metastatic breast cancer as a cause of death!”
More posts featuring Paolo Tarantino.